Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
International Retrospective Study of Allogeneic Hematopoietic Cell Transplantation for Activated Pi3k-Delta Syndrome Publisher Pubmed



Dimitrova D1 ; Nademi Z2, 3 ; Maccari ME4, 5 ; Ehl S4, 5 ; Uzel G6 ; Tomoda T7 ; Okano T7 ; Imai K8 ; Carpenter B9 ; Ip W10, 11 ; Rao K12 ; Worth AJJ10, 11 ; Laberko A13 ; Mukhina A13 Show All Authors
Authors
  1. Dimitrova D1
  2. Nademi Z2, 3
  3. Maccari ME4, 5
  4. Ehl S4, 5
  5. Uzel G6
  6. Tomoda T7
  7. Okano T7
  8. Imai K8
  9. Carpenter B9
  10. Ip W10, 11
  11. Rao K12
  12. Worth AJJ10, 11
  13. Laberko A13
  14. Mukhina A13
  15. Neven B14, 15, 16
  16. Moshous D14, 15, 16
  17. Speckmann C4, 5
  18. Warnatz K5
  19. Wehr C5, 17
  20. Abolhassani H18, 19
  21. Aghamohammadi A19
  22. Bleesing JJ20
  23. Dara J21
  24. Dvorak CC21
  25. Ghosh S22
  26. Kang HJ23
  27. Markelj G24
  28. Modi A25
  29. Bayer DK26
  30. Notarangelo LD6
  31. Schulz A27
  32. Garciaprat M28
  33. Solerpalacin P28
  34. Karakukcu M29
  35. Yilmaz E29
  36. Gambineri E30, 31
  37. Menconi M32
  38. Masmas TN33
  39. Holm M34
  40. Bonfim C35
  41. Prando C36
  42. Hughes S37
  43. Jolles S38
  44. Morris EC39
  45. Kapoor N40
  46. Koltan S41
  47. Paneesha S42
  48. Steward C43
  49. Wynn R37
  50. Duffner U44, 45
  51. Gennery AR2, 3
  52. Lankester AC46
  53. Slatter M2, 3
  54. Kanakry JA1

Source: Journal of Allergy and Clinical Immunology Published:2022


Abstract

Background: Activated phosphoinositide 3-kinase delta syndrome (APDS) is a combined immunodeficiency with a heterogeneous phenotype considered reversible by allogeneic hematopoietic cell transplantation (HCT). Objectives: This study sought to characterize HCT outcomes in APDS. Methods: Retrospective data were collected on 57 patients with APDS1/2 (median age, 13 years; range, 2-66 years) who underwent HCT. Results: Pre-HCT comorbidities such as lung, gastrointestinal, and liver pathology were common, with hematologic malignancy in 26%. With median follow-up of 2.3 years, 2-year overall and graft failure–free survival probabilities were 86% and 68%, respectively, and did not differ significantly by APDS1 versus APDS2, donor type, or conditioning intensity. The 2-year cumulative incidence of graft failure following first HCT was 17% overall but 42% if mammalian target of rapamycin inhibitor(s) (mTORi) were used in the first year post-HCT, compared with 9% without mTORi. Similarly, 2-year cumulative incidence of unplanned donor cell infusion was overall 28%, but 65% in the context of mTORi receipt and 23% without. Phenotype reversal occurred in 96% of evaluable patients, of whom 17% had mixed chimerism. Vulnerability to renal complications continued post-HCT, adding new insights into potential nonimmunologic roles of phosphoinositide 3-kinase not correctable through HCT. Conclusions: Graft failure, graft instability, and poor graft function requiring unplanned donor cell infusion were major barriers to successful HCT. Post-HCT mTORi use may confer an advantage to residual host cells, promoting graft instability. Longer-term post-HCT follow-up of more patients is needed to elucidate the kinetics of immune reconstitution and donor chimerism, establish approaches that reduce graft instability, and assess the completeness of phenotype reversal over time. © 2021
Other Related Docs
7. Management of Inborn Errors of Immunity in the Genomic Era, Turkish Archives of Pediatrics (2022)
10. Pik3r1 Mutation Associated With Hyper Igm (Apds2 Syndrome): A Case Report and Review of the Literature, Endocrine# Metabolic and Immune Disorders - Drug Targets (2019)
15. Autoimmunity in Primary T-Cell Immunodeficiencies, Expert Review of Clinical Immunology (2016)
19. Pulmonary Manifestations of Predominantly Antibody Deficiencies, Pulmonary Manifestations of Primary Immunodeficiency Diseases (2018)
20. Application of Flow Cytometry in Predominantly Antibody Deficiencies, Endocrine# Metabolic and Immune Disorders - Drug Targets (2021)